Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
News|Articles|October 24, 2022
Daily Dose: Delay Before Start of Triple Therapy Raises Risk for COPD Exacerbations
Author(s)Sydney Jennings
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On October 21, 2022, we reviewed a study presented at the American College of Chest Physicians (CHEST) 2022 Annual Meeting, that assessed whether prompt initiation of triple therapy (TT) following a second moderate exacerbation within 12 months was associated with a lower risk of subsequent COPD exacerbations.
The study
There were 17 988 adults aged ≥40 years with a diagnosis of COPD included in the study. Patients were stratified into 3 groups based on timing of a TT prescription after the index exacerbation:
Prompt within 30 days (25.6%)
Delayed 31-180 days (42.7%)
Very delayed 181+ days (31.7%)
The results
Proportion of patients who had ≥1 exacerbations by length of TT initiation delay:
Prompt: 66.6%
Delayed: 81.3%
Very delayed: 88.5% (p<.01)
Clinical implications
"Delays in starting triple therapy may introduce avoidable risks of future exacerbations including hospitalizations. These results support a more proactive approach to the management of COPD following moderate exacerbation events, particularly initiation of triple therapy," concluded researchers.
Click here for the full study review.
Advertisement
Related to this article
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
Advertisement
Advertisement